TORONTO--(BUSINESS WIRE)--Highland Therapeutics Inc. (“Highland”), a pharmaceutical company, today announced that the U.S. Patent and Trademark Office (“USPTO”) has issued two patents for HLD-200, a novel formulation of methylphenidate designed to be taken once-daily in the evening with the objective of controlling symptoms of ADHD immediately upon awakening and throughout the day.
Patent No. 8,916,588 “Methods of Treatment for Attention Deficit Hyperactivity Disorder” and Patent No. 8,927,010 “Compositions for Treatment of Attention Deficit Hyperactivity Disorder” are owned by Highland’s wholly owned subsidiary, Ironshore Pharmaceuticals & Development, Inc. (“Ironshore”) and will expire in 2032. Ironshore intends to list the patents in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, commonly referred to as the Orange Book, upon U.S. regulatory approval of HLD-200.
“The issuance of these patents is a testament to the success of our intellectual property strategy and underscores the novelty of our DELEXIS® technology,” said David Lickrish, Highland’s President and Chief Executive Officer. “We have recently filed new patent applications, and expect to file additional applications in 2015, to further broaden the Company's patent portfolio. Given the recently announced Phase III data, we continue to believe that HLD-200 can fundamentally change treatment paradigms in ADHD and intend to position the drug as the emerging standard of care.”
About Highland Therapeutics Inc.
Highland Therapeutics Inc. is a specialty pharmaceutical company that, through its wholly owned subsidiary Ironshore Pharmaceuticals & Development, Inc., is leveraging its proprietary technology, DELEXIS®, to optimize the delivery of previously approved drug products. The Company’s lead product candidates, HLD-200 and HLD-100, are novel formulations of the psychostimulants (methylphenidate and amphetamine, respectively) used to treat ADHD and are being developed to address a prevalent unmet medical need in the treatment of the disease – inadequate symptom control during the morning routine. Intended for nighttime dosing, DELEXIS® is designed to provide a consistent delay in the initial release of the active drug, followed by a period of extended release; with the objective of providing control of ADHD symptoms immediately upon wakening and throughout the day.
Highland Therapeutics Inc. is a client of MaRS Discovery District’s Health Venture Services group, which provides advisory services, connections to talent, customer & capital networks, and market intelligence to high-impact, Ontario-based life sciences ventures, helping them commercialize their ideas and build globally competitive companies.
For further information, please visit the Company’s website at www.highlandtherapeutics.com.
This press release contains forward-looking information, which reflects Highland’s current expectations regarding future events. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond Highland’s control that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. These forward-looking statements are made as of the date of this press release and, except as expressly required by applicable law, Highland assumes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.